期刊
ALLERGOLOGY INTERNATIONAL
卷 72, 期 2, 页码 316-323出版社
JAPANESE SOC ALLERGOLOGY
DOI: 10.1016/j.alit.2022.08.008
关键词
Classification criteria; Diagnosis; Diagnostic score; Eosinophilia; Eosinophilic granulomatosis with polyangiitis
This study proposed a scoring system to differentiate eosinophilic granulomatosis with polyangiitis (EGPA) from other eosinophilic disorders. Through unsupervised hierarchical clustering and principal component analysis, two distinct clusters were identified among 58 patients with eosinophilia-related diseases. Based on these features, a 16-point scoring system was established and validated in a separate cohort.
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of systemic vasculitis with eosinophilic inflammation. However, existing classification criteria are all designed to classify EGPA among vasculitis and there is no established method distinguishing EGPA from other eosinophilic dis-orders. The aim of the present study was to propose a scoring system to differentiate EGPA among eosinophilic disorders.Methods: Non-supervised hierarchical clustering using Ward's method and principal component analysis (PCA) were performed for 19 clinical parameters of 58 patients with eosinophilia-related diseases at a tertiary university hospital. The newly proposed scoring system was externally validated in 40 patients at another tertiary institution.Results: Two distinct clusters were identified, and clinical features including peripheral neuropathy, asthma, skin involvement, lung involvement, rheumatoid factor (RF) positivity, myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA) positivity, IgE elevation, C-reactive protein (CRP) eleva-tion, and vasculitis pathological findings were predominantly observed in one of these clusters (p < 0.05). Ten features defining the cluster with a high rate of vasculitis were weighted by PCA to create the E-CASE (EGPA classification among systemic eosinophilia) scoring system, on a 16-point scale. Based on the distribution of scores in the primary cohort, we defined an E-CASE score >= 12 as positive, < 8 as negative, and 9-11 as undeterminable. The sensitivity and specificity of the E-CASE score in the validation cohort were 93.3% and 100%, respectively. Conclusions: We developed and verified a novel scoring system for differentiating EGPA from other types of eosinophilic disorders.(c) 2022 Japanese Society of Allergology. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据